Home › Filings & Releases › June 2026
Filings & Releases — June 2026
739 documents from 241 companies (219 releases) · updated Nov 7, 2026
No documents match these filters.
Tuesday, June 3025
- XERSXeris Biopharma8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- UNCYUnicycive TherapeuticsReleaseUnicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)BD extracted 1 program update from this document → UNCY pipeline
- TENXTenax Therapeutics8-KCurrent report: material agreement
- STOKStoke Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- SRPTSarepta TherapeuticsReleaseSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
- SEPNSepterna8-KCurrent report: shareholder vote
- RCKTRocket Pharmaceuticals8-KCurrent report: officer / director change
- PRQRProQR TherapeuticsSCHEDULE 13D/A13D amendment
- NVCTNuvectis Pharma8-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
- NVCTNuvectis Pharma424B5Prospectus supplement (offering)
- NGNENeurogene424B5Prospectus supplement (offering)
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- KTTAPasithea TherapeuticsReleasePasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus
- KAPAKairos Pharma8-KCurrent report: shareholder vote
- IRONDisc Medicine8-KCurrent report: material agreement, debt / obligation
- CRNXCrinetics PharmaceuticalsReleaseCrinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026company site may be offline after the acquisition
- COGTCogent BiosciencesReleaseCogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)BD extracted 1 program update from this document → COGT pipeline
- CATXPerspective TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- APVOAptevo Therapeutics8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
- AKBAAkebia TherapeuticsReleaseU.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
- AKBAAkebia Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → AKBA pipeline
- ACIUAC Immune6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ABVXAbivaxPOSASRPOSASR
- ABVXAbivaxFWPFree writing prospectus (offering terms)
- ABVXAbivax424B5Prospectus supplement (offering)
Monday, June 2938
- ZYMEZymeworks8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
- VYGRVoyager TherapeuticsReleaseVoyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
- VTVTvTv Therapeutics8-KCurrent report: shareholder vote
- VRDNViridian Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- TENXTenax Therapeutics8-KCurrent report: officer / director change, other events
- TARAProtara Therapeutics8-KCurrent report: officer / director change
- SPRBSpruce BiosciencesReleaseSpruce Biosciences Joins the Russell 3000® Index
- SGMTSagimet BiosciencesReleaseSagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
- REPLReplimune GroupS-8Employee plan registration
- REPLReplimune GroupReleaseReplimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate UpdateBD extracted 2 program updates from this document → REPL pipeline
- REPLReplimune Group8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- REPLReplimune Group10-KAnnual reportBD extracted 1 program update from this document → REPL pipeline
- NVCTNuvectis Pharma8-KCurrent report: other events
- NVCTNuvectis Pharma424B5Prospectus supplement (offering)
- NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JUNE 29, 2026
- NGNENeurogene8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → NGNE pipeline
- NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1
- MLTXMoonLake ImmunotherapeuticsSCHEDULE 13D/A13D amendment
- LXEOLexeo Therapeutics8-KCurrent report: shareholder vote
- LRMRLarimar TherapeuticsReleaseLarimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s AtaxiaBD extracted 2 program updates from this document → LRMR pipeline
- LRMRLarimar Therapeutics8-KCurrent report: other events · EX-99.1
- IMUXImmunic8-KCurrent report: officer / director change, shareholder vote
- HELPHelus PharmaReleaseHelus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
- HELPHelus Pharma6-KForeign issuer report · EX-99.1
- HELPHelus Pharma40-FAnnual report (Canadian)
- GANXGain TherapeuticsReleaseGain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
- GANXGain Therapeutics8-KCurrent report: other events
- FDMT4D Molecular Therapeutics8-KCurrent report: material agreement, debt / obligation
- EVMNEvommune8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- EVMNEvommune424B3Prospectus (resale / update)
- DBVTDBV TechnologiesReleaseDBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filingvia aggregator
- DBVTDBV Technologies8-KCurrent report: other events · EX-99.1
- CUECue BiopharmaCORRESPCORRESP
- CRBUCaribou BiosciencesReleaseCaribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- BDTXBlack Diamond Therapeutics8-KCurrent report: shareholder vote
- BCRXBiocryst Pharmaceuticals8-KCurrent report: exit / restructuring costs, Reg FD disclosure · EX-99.1 PRESS RELEASE
- AUTLAutolus Therapeutics8-KCurrent report: shareholder vote
- ANABAnaptysBioDEFA14AProxy soliciting material
- ANABAnaptysBioDEF 14AProxy statement
- ANABAnaptysBioARSAnnual report to shareholders
- ABVXAbivax6-KForeign issuer report · EX-99.1
- AARDAardvark TherapeuticsPRE 14APRE 14A
Friday, June 2622
- WVEWave Life Sciences8-KCurrent report: shareholder vote
- VRDNViridian TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- VRDNViridian TherapeuticsReleaseViridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye DiseaseBD extracted 1 program update from this document → VRDN pipeline
- SYRESpyre TherapeuticsS-3ASRAutomatic shelf registration
- SCYXScynexis8-KCurrent report: charter / bylaws / fiscal year, shareholder vote, other events
- REPLReplimune GroupReleaseReplimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
- REPLReplimune Group8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- PRQRProQR Therapeutics424B5Prospectus supplement (offering)
- PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
- OTLKOutlook Therapeutics8-KCurrent report: listing notice
- OMEROmerosReleaseOmeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMABD extracted 1 program update from this document → OMER pipeline
- MDNAFMedicenna TherapeuticsReleaseMedicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational HighlightsBD extracted 2 program updates from this document → MDNAF pipeline
- LRMRLarimar TherapeuticsReleaseLarimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
- LENZLENZ TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- KYMRKymera TherapeuticsSCHEDULE 13D/A13D amendment
- JBIOJade BiosciencesReleaseJUNE 26, 2026 Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
- JBIOJade Biosciences8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- HURATuHURA BiosciencesPRE 14APRE 14A
- GHRSGH Research6-KForeign issuer report
- CTNMContineum Therapeutics8-KCurrent report: shareholder vote
- CRVOCervoMedSCHEDULE 13GPassive >5% holder (13G)
- CLDXCelldex TherapeuticsS-8Employee plan registration
- CLDXCelldex Therapeutics8-KCurrent report: officer / director change, shareholder vote
- CAPRCapricor Therapeutics8-KCurrent report: other events · EX-99.1
- BCTXBriaCell Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1BD extracted 1 program update from this document → BCTX pipeline
- APGEApogee TherapeuticsDEFA14AProxy soliciting material
Thursday, June 2536
- TSHATaysha Gene TherapiesReleaseTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific MeetingBD extracted 1 program update from this document → TSHA pipeline
- TSHATaysha Gene Therapies8-KCurrent report: material agreement, other events · EX-99.1
- TSHATaysha Gene Therapies424B5Prospectus supplement (offering)
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED JUNE 25, 2026
- SLSSELLAS Life Sciences Group8-KCurrent report: officer / director change
- RYTMRhythm Pharmaceuticals8-KCurrent report: shareholder vote
- QUREuniQureReleaseuniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Sharesvia aggregator
- QTTBQ32 BioS-3Shelf registration
- PTNPalatin TechnologiesDEF 14AProxy statement
- PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026via aggregator
- OMEROmeros8-KCurrent report: shareholder vote
- OCSOculis Holding6-KForeign issuer report · EX-99.1
- NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
- NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
- NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JUNE 25, 2026
- MLTXMoonLake Immunotherapeutics8-KCurrent report: material agreement
- MESOMesoblast6-KForeign issuer report · EX-99.1
- MAIAMAIA BiotechnologyReleaseMAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
- KYMRKymera TherapeuticsReleaseBROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expecBD extracted 1 program update from this document → KYMR pipeline
- KYMRKymera Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- KROSKeros Therapeutics8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- IXHLIncannex HealthcareReleaseIncannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
- IXHLIncannex Healthcare8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF JUNE 25, 2026
- IMTXImmaticsS-8Employee plan registration
- HELPHelus PharmaSUPPLSUPPL
- HELPHelus PharmaReleaseHelus Pharma™ Announces Closing of US$50 Million Underwritten Offering
- HELPHelus Pharma6-KForeign issuer report · EX-99.1
- HELPHelus Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- GANXGain Therapeutics8-KCurrent report: shareholder vote
- DRTSAlpha Tau Medical6-KForeign issuer report
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- CUECue BiopharmaUPLOADUPLOAD
- CRDLCardiol TherapeuticsReleaseCardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
- CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 NEWS RELEASE DATED JUNE 25, 2026
- COYACoya Therapeutics8-KCurrent report: shareholder vote
- BCTXBriaCell TherapeuticsReleaseBriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™via aggregator
- ATAIAtai BeckleyReleaseAtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Marketscompany site may be offline after the acquisition
- ARVNArvinas8-KCurrent report: shareholder vote
Wednesday, June 2434
- WVEWave Life SciencesReleaseWave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic DiseasesBD extracted 1 program update from this document → WVE pipeline
- TSHATaysha Gene TherapiesReleaseTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- TSHATaysha Gene TherapiesReleaseTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- TSHATaysha Gene Therapies424B5Prospectus supplement (offering)
- SLDBSolid BiosciencesSCHEDULE 13D/A13D amendment
- QUREuniQureReleaseuniQure Announces Pricing of Upsized $225 Million Public Offeringvia aggregator
- QUREuniQure8-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
- QUREuniQure424B5Prospectus supplement (offering)
- PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762via aggregator
- NRXPNRX PharmaceuticalsReleaseKadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisitionvia aggregator
- MPLTMapLight Therapeutics8-KCurrent report: shareholder vote
- MLTXMoonLake Immunotherapeutics424B5Prospectus supplement (offering)
- KYMRKymera TherapeuticsReleaseBruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmac
- KYMRKymera Therapeutics8-KCurrent report: shareholder vote
- IRONDisc Medicine8-KCurrent report: shareholder vote
- IONSIonis Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- HELPHelus PharmaReleaseHelus Pharma™ Announces US$50 Million Underwritten Offering
- HELPHelus PharmaReleaseHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
- HELPHelus PharmaFWPFree writing prospectus (offering terms)
- FHTXFoghorn Therapeutics8-KCurrent report: shareholder vote
- ELVNEnliven TherapeuticsSCHEDULE 13D/A13D amendment
- ELTXElicio Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1BD extracted 1 program update from this document → ELTX pipeline
- DFTXDefinium Therapeutics8-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
- DFTXDefinium Therapeutics424B5Prospectus supplement (offering)
- CGTXCognition TherapeuticsReleaseCognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting MinutesBD extracted 1 program update from this document → CGTX pipeline
- CGTXCognition Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- CCCCC4 Therapeutics8-KCurrent report: shareholder vote
- CADLCandel Therapeutics8-KCurrent report: shareholder vote
- ADCTADC Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- ABSIAbsciReleaseAbsci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investorsvia aggregator
- ABSIAbsciReleaseAbsci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)BD extracted 1 program update from this document → ABSI pipeline
- ABSIAbsci8-KCurrent report: other events · EX-99.1
- ABSIAbsci8-KCurrent report: material agreement, other events · EX-99.1
- ABSIAbsci424B5Prospectus supplement (offering)
Tuesday, June 2324
- VSTMVerastem8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- TNGXTango Therapeutics8-KCurrent report: officer / director change · EX-99.1
- SYRESpyre TherapeuticsSCHEDULE 13D/A13D amendment
- QNRXQuoin Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- PCVXVaxcyte8-KCurrent report: officer / director change
- OLMAOlema Pharmaceuticals8-KCurrent report: shareholder vote
- NVCTNuvectis Pharma8-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
- KTTAPasithea TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- JANXJanux Therapeutics8-KCurrent report: other events
- INMBInmune Bio8-KCurrent report: other events · EX-99.1 PRESS RELEASE DATED JUNE 23, 2026
- INKTMiNK Therapeutics8-KCurrent report: shareholder vote
- IDYAIDEAYA Biosciences8-KCurrent report: shareholder vote, other events
- FBIOFortress Biotech8-KCurrent report: shareholder vote
- ENTAEnanta PharmaceuticalsReleaseEnanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
- ENTAEnanta Pharmaceuticals8-KCurrent report: other events
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JUNE 23, 2026
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
- DBVTDBV TechnologiesReleaseDBV Technologies Announces Inclusion in the Euronext Tech Leaders Indexvia aggregator
- CRDLCardiol TherapeuticsReleaseCardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
- CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 NEWS RELEASE DATED JUNE 23, 2026
- CMPXCompass Therapeutics8-KCurrent report: charter / bylaws / fiscal year
- ARTVArtiva BiotherapeuticsReleaseArtiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- APGEApogee TherapeuticsSCHEDULE 13D/A13D amendment
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026BD extracted 1 program update from this document → AMLX pipeline
- AGMBAgomab Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
Monday, June 2250
- UNCYUnicycive TherapeuticsDEFA14AProxy soliciting material
- UNCYUnicycive Therapeutics8-KCurrent report: shareholder vote
- TSHATaysha Gene TherapiesReleaseTaysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett SyndromeBD extracted 1 program update from this document → TSHA pipeline
- TSHATaysha Gene Therapies8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → TSHA pipeline
- TNGXTango TherapeuticsReleaseTango Therapeutics Appoints Robert Azelby to Board of Directors
- SPRBSpruce BiosciencesReleaseSpruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
- RVMDRevolution Medicines8-KCurrent report: officer / director change, shareholder vote
- RLMDRelmada TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- QUREuniQureReleaseuniQure Announces $150 Million Proposed Public Offeringvia aggregator
- QUREuniQure8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → QURE pipeline
- QUREuniQure424B5Prospectus supplement (offering)
- PEPGPepGen8-KCurrent report: shareholder vote
- ORICOric Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote
- NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
- MPLTMapLight Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- MLTXMoonLake Immunotherapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 PRESS RELEASE, DATED JUNE 21, 2026
- MLTXMoonLake Immunotherapeutics424B5Prospectus supplement (offering)
- LEGNLegend Biotech6-KForeign issuer report · EX-99.1
- KYTXKyverna TherapeuticsReleaseKyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
- HROWHarrow8-KCurrent report: shareholder vote
- GNLXGenelux8-KCurrent report: shareholder vote
- FDMT4D Molecular Therapeutics8-KCurrent report: shareholder vote
- EYPTEyePoint8-KCurrent report: officer / director change, shareholder vote
- EXELExelixisReleaseExelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancervia aggregator
- ELVNEnliven TherapeuticsSCHEDULE 13G/A13G amendment
- ELDNEledon Pharmaceuticals8-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- DYNDyne TherapeuticsReleaseDyne Therapeutics Appoints Barry Greene to Board of Directors
- DYNDyne Therapeutics8-KCurrent report: officer / director change
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics, Inc. Announces Proposed Public Offering
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive DisorderBD extracted 1 program update from this document → DFTX pipeline
- DFTXDefinium Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- DFTXDefinium Therapeutics424B5Prospectus supplement (offering)
- CTMXCytomX Therapeutics8-KCurrent report: officer / director change, charter / bylaws / fiscal year, shareholder vote
- CRVOCervoMedReleaseCervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
- CRVOCervoMed8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- CRVOCervoMed8-KCurrent report: material agreement, unregistered sale of equity, other events · EX-99.1 EXHIBIT 99.1
- CRVOCervoMed424B5Prospectus supplement (offering)
- CRNXCrinetics Pharmaceuticals8-KCurrent report: shareholder vote
- CBIOCrescent Biopharma424B3Prospectus (resale / update)
- CBIOCrescent Biopharma10-Q/AQuarterly report (amended)
- BBOTBridgeBio Oncology Therapeutics8-KCurrent report: officer / director change, shareholder vote
- BBOTBridgeBio Oncology Therapeutics424B3Prospectus (resale / update)
- ARVNArvinas8-KCurrent report: officer / director change
- APVOAptevo TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- APGEApogee TherapeuticsReleaseAbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfoliocompany site may be offline after the acquisition; linked to the SEC copy · original
- APGEApogee TherapeuticsDEFA14AProxy soliciting material
- APGEApogee TherapeuticsDEFA14AProxy soliciting material
- APGEApogee Therapeutics8-KCurrent report: material agreement, shareholder vote, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- APGEApogee Therapeutics8-KCurrent report: material agreement
- ANABAnaptysBio8-KCurrent report: material agreement
- ALLOAllogene Therapeutics8-KCurrent report: shareholder vote, other events
- ALLOAllogene Therapeutics424B5Prospectus supplement (offering)
- AKBAAkebia Therapeutics8-KCurrent report: shareholder vote
Sunday, June 211
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026BD extracted 1 program update from this document → DFTX pipeline
Friday, June 191
- QUREuniQureReleaseuniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe EpilepsyBD extracted 1 program update from this document → QURE pipeline
Thursday, June 1835
- ZURAZura Bio8-KCurrent report: officer / director change, shareholder vote
- ZNTLZentalis Pharmaceuticals8-KCurrent report: shareholder vote
- XNCRXencor8-KCurrent report: shareholder vote
- SLSSELLAS Life Sciences Group8-KCurrent report: shareholder vote
- SIONSionna Therapeutics8-KCurrent report: shareholder vote
- SABSSAB Biotherapeutics8-KCurrent report: shareholder vote
- RXRXRecursion Pharmaceuticals8-KCurrent report: shareholder vote
- RLMDRelmada TherapeuticsS-8Employee plan registration
- PTGXProtagonist Therapeutics8-KCurrent report: officer / director change, shareholder vote
- PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026via aggregator
- PCSAProcessa PharmaceuticalsDEF 14AProxy statement
- OMEROmeros8-KCurrent report: other events
- MPLTMapLight Therapeutics8-KCurrent report: officer / director change
- MAIAMAIA BiotechnologyReleaseMAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
- LGVNLongeveronReleaseNew Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)BD extracted 1 program update from this document → LGVN pipeline
- LEGNLegend Biotech424B5Prospectus supplement (offering)
- KPRXKiora PharmaceuticalsReleaseKiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
- KPRXKiora Pharmaceuticals8-KCurrent report: Reg FD disclosure · EX-99.1
- IMTXImmatics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- GRCEGrace TherapeuticsReleaseGrace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business UpdateBD extracted 1 program update from this document → GRCE pipeline
- GRCEGrace Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- GRCEGrace Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- GRCEGrace Therapeutics10-KAnnual reportBD extracted 1 program update from this document → GRCE pipeline
- GPCRStructure Therapeutics8-KCurrent report: shareholder vote
- ENTAEnanta PharmaceuticalsReleaseEnanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
- ENTAEnanta Pharmaceuticals8-KCurrent report: Reg FD disclosure · EX-99.1BD extracted 1 program update from this document → ENTA pipeline
- CUECue BiopharmaS-3Shelf registration
- CRVOCervoMedReleaseCervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
- CRVOCervoMedReleaseCervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
- CRVOCervoMed8-KCurrent report: other events
- CRBUCaribou Biosciences8-KCurrent report: shareholder vote
- CGTXCognition Therapeutics8-KCurrent report: shareholder vote
- BEAMBeam TherapeuticsReleaseBeam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug AdministrationBD extracted 1 program update from this document → BEAM pipeline
- BCYCBicycle Therapeutics8-KCurrent report: shareholder vote
- AGIOAgios PharmaceuticalsS-8Employee plan registration
- AGIOAgios Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote
- ACETAdicet Bio8-KCurrent report: shareholder vote
Wednesday, June 1720
- VSTMVerastem8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- TVTXTravere TherapeuticsS-8Employee plan registration
- RNACCartesian Therapeutics8-KCurrent report: shareholder vote
- QUREuniQureReleaseuniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
- QUREuniQure8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- LXEOLexeo TherapeuticsReleaseLexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxiacompany site may be offline after the acquisition
- LQDALiquidia8-KCurrent report: shareholder vote
- LEGNLegend BiotechF-6EFF-6EF
- LEGNLegend Biotech424B5Prospectus supplement (offering)
- IRDOpus Genetics424B2Prospectus supplement
- INMBInmune Bio8-KCurrent report: officer / director change, shareholder vote
- HURATuHURA Biosciences8-KCurrent report: shareholder nominations
- GOSSGossamer BioReleaseGossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
- GOSSGossamer Bio8-KCurrent report: Reg FD disclosure · EX-99.1
- ELVNEnliven TherapeuticsSCHEDULE 13D/A13D amendment
- ELTXElicio Therapeutics8-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → ELTX pipeline
- ELOXEloxx PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- ELOXEloxx PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- DYNDyne TherapeuticsReleaseDyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
- DYNDyne Therapeutics8-KCurrent report: material agreement, debt / obligation
- CUECue BiopharmaEFFECTRegistration effective
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ARDXArdelyx8-KCurrent report: officer / director change, shareholder vote
- ACRVAcrivon Therapeutics8-KCurrent report: officer / director change, shareholder vote
- ABOSAcumen PharmaceuticalsReleaseJCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platformvia aggregator
Tuesday, June 1625
- TVTXTravere TherapeuticsReleaseTravere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
- TVTXTravere Therapeutics8-KCurrent report: officer / director change
- SLSSELLAS Life Sciences GroupS-8Employee plan registration
- QTTBQ32 Bio8-KCurrent report: shareholder vote
- PCVXVaxcyte8-KCurrent report: shareholder vote
- OTLKOutlook TherapeuticsReleaseOutlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
- OTLKOutlook Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
- NBPNovaBridge Biosciences6-KForeign issuer report
- NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1
- NBPNovaBridge Biosciences20-F/AAnnual report (foreign, amended)
- KTTAPasithea TherapeuticsReleasePasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
- IRDOpus Genetics8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- IRDOpus Genetics8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- IPSCCentury Therapeutics8-KCurrent report: officer / director change
- ELOXEloxx PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- ELOXEloxx PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- DTILPrecision Biosciences8-KCurrent report: material agreement, debt / obligation
- DFTXDefinium TherapeuticsS-8Employee plan registration
- CINGCingulateReleaseCingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
- CINGCingulate8-KCurrent report: Reg FD disclosure · EX-99.1
- CGTXCognition TherapeuticsReleaseCognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
- CGEMCullinan Therapeutics8-KCurrent report: shareholder vote
- CADLCandel Therapeutics8-KCurrent report: officer / director change
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ARVNArvinas8-KCurrent report: other events
- ALTAltimmune8-KCurrent report: other events
- ABOSAcumen PharmaceuticalsReleaseAcumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
- ABOSAcumen Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 2 program updates from this document → ABOS pipeline
Monday, June 1528
- UNCYUnicycive TherapeuticsEFFECTRegistration effective
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED JUNE 15, 2026
- TARAProtara Therapeutics8-KCurrent report: shareholder vote
- SYRESpyre TherapeuticsReleaseSpyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
- SYRESpyre Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → SYRE pipeline
- SPRBSpruce BiosciencesReleaseSpruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
- RYTMRhythm Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → RYTM pipeline
- QUREuniQure8-KCurrent report: officer / director change, charter / bylaws / fiscal year, shareholder vote
- OMEROmerosReleaseOmeros Announces Webcast Details for Annual Meeting of Shareholders
- NTLAIntellia Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- MISTMilestone Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote
- MGTXMeiraGTx8-KCurrent report: shareholder vote
- LXEOLexeo TherapeuticsReleaseLexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxiacompany site may be offline after the acquisition; linked to the SEC copy · original
- LXEOLexeo Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- LEGNLegend Biotech6-KForeign issuer report · EX-99.1 PRESS RELEASE
- KTTAPasithea TherapeuticsReleasePasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
- IRDOpus GeneticsEFFECTRegistration effective
- INBXInhibrx Biosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- IMRXImmuneeringReleaseImmuneering Appoints Andrew Gengos as Chief Financial Officer
- IMRXImmuneering8-KCurrent report: officer / director change
- FATEFate Therapeutics8-KCurrent report: officer / director change, shareholder vote
- ELTXElicio Therapeutics8-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → ELTX pipeline
- ELOXEloxx PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- CUECue BiopharmaCORRESPCORRESP
- CRVOCervoMedSCHEDULE 13D/A13D amendment
- CRVOCervoMed8-KCurrent report: Reg FD disclosure
- CHRSCoherus Oncology8-KCurrent report: auditor change
- BLTEBelite Bio6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ARTVArtiva BiotherapeuticsSCHEDULE 13D/A13D amendment
Sunday, June 144
- CRNXCrinetics PharmaceuticalsReleaseCrinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026BD extracted 1 program update from this document → CRNX pipelinecompany site may be offline after the acquisition
- CRNXCrinetics PharmaceuticalsReleaseCrinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly ControlBD extracted 1 program update from this document → CRNX pipelinecompany site may be offline after the acquisition
- CLDXCelldex TherapeuticsReleaseCelldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual
- CLDXCelldex TherapeuticsReleaseCelldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual MeetingBD extracted 1 program update from this document → CLDX pipeline
Saturday, June 132
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026BD extracted 1 program update from this document → RYTM pipeline
- NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaBD extracted 1 program update from this document → NTLA pipeline
Friday, June 1232
- VORVor Biopharma8-KCurrent report: shareholder vote
- TGTXTg Therapeutics8-KCurrent report: shareholder vote
- SMMTSummit Therapeutics8-KCurrent report: shareholder vote
- SGMTSagimet Biosciences8-KCurrent report: officer / director change, shareholder vote
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
- RCUSArcus Biosciences8-KCurrent report: shareholder vote
- RCKTRocket PharmaceuticalsReleaseRocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
- RCKTRocket Pharmaceuticals8-KCurrent report: acquisition / disposition, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- RAREUltragenyx PharmaceuticalS-8Employee plan registration
- NVCTNuvectis Pharma8-KCurrent report: shareholder vote
- LENZLENZ Therapeutics8-KCurrent report: shareholder vote
- LCTXLineage Cell Therapeutics8-KCurrent report: shareholder vote, other events
- KYMRKymera TherapeuticsReleaseOral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies KT-621 pBD extracted 1 program update from this document → KYMR pipeline
- JANXJanux Therapeutics8-KCurrent report: shareholder vote
- IPSCCentury Therapeutics8-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- IONSIonis Pharmaceuticals8-KCurrent report: other events
- IMNMImmunome8-KCurrent report: shareholder vote
- ELVNEnliven Therapeutics8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
- ELVNEnliven Therapeutics424B5Prospectus supplement (offering)
- DFTXDefinium Therapeutics8-KCurrent report: officer / director change, shareholder vote
- CRVSCorvus Pharmaceuticals8-KCurrent report: shareholder vote
- CRVOCervoMedReleaseCervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
- COGTCogent BiosciencesReleaseCogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) CongressBD extracted 1 program update from this document → COGT pipeline
- COGTCogent BiosciencesReleaseCogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) CongressBD extracted 1 program update from this document → COGT pipeline
- CLYMClimb Bio8-KCurrent report: material agreement, other events
- CLYMClimb Bio424B5Prospectus supplement (offering)
- BIOABioAge Labs8-KCurrent report: shareholder vote
- BCRXBiocryst Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- APGEApogee Therapeutics8-KCurrent report: shareholder vote
- ANNXAnnexon8-KCurrent report: shareholder vote
- ABSIAbsciReleaseMindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discoveryvia aggregator
- AARDAardvark Therapeutics8-KCurrent report: officer / director change
Thursday, June 1138
- XERSXeris Biopharma8-KCurrent report: unregistered sale of equity, other events · EX-99.1
- VYGRVoyager TherapeuticsReleaseVoyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
- UNCYUnicycive TherapeuticsUPLOADUPLOAD
- UNCYUnicycive TherapeuticsCORRESPCORRESP
- SMMTSummit Therapeutics8-KCurrent report: Reg FD disclosure
- PALIPalisade Bio8-KCurrent report: officer / director change, charter / bylaws / fiscal year, shareholder vote
- OVIDOvid Therapeutics8-KCurrent report: shareholder vote
- OCGNOcugen8-KCurrent report: shareholder vote, other events
- NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JUNE 11, 2026
- NRIXNurix TherapeuticsReleaseNurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
- NRIXNurix Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → NRIX pipeline
- NKTXNkarta8-KCurrent report: shareholder vote
- MDNAFMedicenna TherapeuticsReleaseMedicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
- KURAKura OncologyReleaseKura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AMLBD extracted 1 program update from this document → KURA pipeline
- KPRXKiora Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote
- JBIOJade Biosciences8-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- IRDOpus GeneticsCORRESPCORRESP
- IMRXImmuneeringReleaseImmuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
- IMRXImmuneering8-KCurrent report: shareholder vote
- HELPHelus PharmaReleaseHelus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
- HELPHelus Pharma6-KForeign issuer report · EX-99.1
- GUTSFractyl Health8-KCurrent report: shareholder vote
- GOSSGossamer BioSCHEDULE 13GPassive >5% holder (13G)
- GOSSGossamer BioSCHEDULE 13GPassive >5% holder (13G)
- GOSSGossamer BioSCHEDULE 13DActivist / >5% holder (13D)
- GLUEMonte Rosa Therapeutics8-KCurrent report: shareholder vote
- ELVNEnliven Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- ELVNEnliven Therapeutics424B5Prospectus supplement (offering)
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JUNE 11, 2026
- CYDYCytoDynReleaseCytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
- CRBUCaribou BiosciencesReleaseCaribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
- CRBUCaribou BiosciencesReleaseCaribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
- CRBUCaribou Biosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 2 program updates from this document → CRBU pipeline
- COGTCogent Biosciences8-KCurrent report: shareholder vote
- CMPXCompass Therapeutics8-KCurrent report: shareholder vote
- CLYMClimb BioReleaseClimb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026BD extracted 1 program update from this document → CLYM pipeline
- CLYMClimb Bio8-KCurrent report: other events
- CCCCC4 TherapeuticsReleaseC4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pret
- CCCCC4 Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → CCCC pipeline
- CABACabaletta Bio8-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- BMEABiomea Fusion8-KCurrent report: shareholder vote
- ACIUAC Immune6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ACIUAC Immune6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
Wednesday, June 1038
- VYGRVoyager Therapeutics8-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- VTVTvTv TherapeuticsDEFA14AProxy soliciting material
- VIRVir BiotechnologyRelease(Opens PDF Titled Vir Biotechnology To Present Complete Week 96 Data From Phase 2 SOLSTICE Clinical Trial In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Congress 2026BD extracted 1 program update from this document → VIR pipeline
- VIRVir BiotechnologyReleaseVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
- VIRVir Biotechnology8-KCurrent report: officer / director change
- TNGXTango TherapeuticsFWPFree writing prospectus (offering terms)
- TNGXTango Therapeutics8-KCurrent report: material agreement
- TNGXTango Therapeutics424B5Prospectus supplement (offering)
- TECXTectonic Therapeutic8-KCurrent report: shareholder vote, other events · EX-99.1
- SNDXSyndax Pharmaceuticals8-KCurrent report: material agreement, debt / obligation, unregistered sale of equity
- SNDXSyndax Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote
- SMMTSummit Therapeutics424B5Prospectus supplement (offering)
- SLDBSolid Biosciences8-KCurrent report: shareholder vote
- RAPPRapport Therapeutics8-KCurrent report: shareholder vote
- PYPDPolyPid6-KForeign issuer report · EX-99.1 NOTICE FOR THE ANNUAL AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON JULY 15, 2
- PRLDPrelude Therapeutics8-KCurrent report: shareholder vote
- PALIPalisade BioS-8Employee plan registration
- NTLAIntellia Therapeutics8-KCurrent report: shareholder vote
- MESOMesoblast6-KForeign issuer report · EX-99.1
- MAZEMaze Therapeutics8-KCurrent report: shareholder vote
- MAIAMAIA BiotechnologyReleaseMAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
- LBRXLB Pharmaceuticals8-KCurrent report: officer / director change
- LBRXLB Pharmaceuticals424B3Prospectus (resale / update)
- IXHLIncannex HealthcareReleaseIncannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
- IXHLIncannex Healthcare8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF JUNE 10, 2026
- IRDOpus GeneticsUPLOADUPLOAD
- IDYAIDEAYA Biosciences8-KCurrent report: other events
- IBRXImmunityBio8-KCurrent report: shareholder vote
- GANXGain TherapeuticsReleaseGain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
- FBRXForte BiosciencesEFFECTRegistration effective
- ELVNEnliven Therapeutics8-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- EIKNEikon Therapeutics8-KCurrent report: officer / director change
- CUECue BiopharmaUPLOADUPLOAD
- CRVOCervoMedReleaseCervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
- CRVOCervoMed8-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- CLDXCelldex TherapeuticsReleaseCelldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual CongressBD extracted 1 program update from this document → CLDX pipeline
- CGEMCullinan TherapeuticsReleaseCullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune DiseasesBD extracted 3 program updates from this document → CGEM pipeline
- CGEMCullinan Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- BCAXBicara Therapeutics8-KCurrent report: shareholder vote
- ANIXAnixa Biosciences10-QQuarterly report
- ALDXAldeyra Therapeutics8-KCurrent report: officer / director change, shareholder vote, Reg FD disclosure · EX-99.1
- AKBAAkebia TherapeuticsReleaseAkebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
Tuesday, June 930
- VRCAVerrica Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote
- TNGXTango TherapeuticsReleaseTango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
- SMMTSummit TherapeuticsS-3ASRAutomatic shelf registration
- SMMTSummit TherapeuticsReleaseSummit Therapeutics Announces Proposed Public Offering of Common Stock
- RNACCartesian Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- RLMDRelmada TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- RLAYRelay Therapeutics8-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JUNE 9, 2026
- MLTXMoonLake Immunotherapeutics8-KCurrent report: officer / director change, shareholder vote
- LGVNLongeveronReleaseLongeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
- LBRXLB Pharmaceuticals8-KCurrent report: shareholder vote
- LBRXLB Pharmaceuticals424B3Prospectus (resale / update)
- KYMRKymera TherapeuticsReleaseFirst-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, In
- JBIOJade BiosciencesSCHEDULE 13D/A13D amendment
- IXHLIncannex HealthcareReleaseIncannex Announces Initiation of Research Coverage by Alliance Global Partners
- IXHLIncannex Healthcare8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF JUNE 9, 2026
- IDYAIDEAYA Biosciences424B5Prospectus supplement (offering)
- GOSSGossamer BioSCHEDULE 13GPassive >5% holder (13G)
- GOSSGossamer BioDEF 14AProxy statement
- ETONEton Pharmaceuticals8-KCurrent report: shareholder vote
- ELOXEloxx Pharmaceuticals424B4Prospectus (IPO / follow-on)
- DBVTDBV TechnologiesReleaseDBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conferencevia aggregator
- CRVOCervoMed8-KCurrent report: shareholder vote
- CLYMClimb BioEFFECTRegistration effective
- CLYMClimb Bio424B3Prospectus (resale / update)
- BCTXBriaCell Therapeutics10-QQuarterly report
- AXSMAxsome Therapeutics8-KCurrent report: officer / director change
- AXSMAxsome Therapeutics8-KCurrent report: shareholder vote
- AUTLAutolus Therapeutics8-KCurrent report: other events · EX-99.1
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ANTXAN2 Therapeutics8-KCurrent report: shareholder vote
- ALDXAldeyra TherapeuticsReleaseAldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
- ACTUActuate TherapeuticsReleaseACTUATE THERAPEUTICS’ ELRAGLUSIB SELECTED FOR EVALUATION IN BEACON2 TRIAL FOR HIGH-RISK PEDIATRIC NEUROBLASTOMABD extracted 1 program update from this document → ACTU pipeline
Monday, June 837
- VORVor BiopharmaReleaseTelitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in ChinaBD extracted 1 program update from this document → VOR pipeline
- VORVor BiopharmaReleaseTelitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
- VORVor Biopharma8-KCurrent report: Reg FD disclosure · EX-99.1
- TNGXTango TherapeuticsReleaseTango Therapeutics Announces Proposed $500 Million Public Offering
- TNGXTango TherapeuticsReleaseTango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
- TNGXTango Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → TNGX pipeline
- TNGXTango Therapeutics424B5Prospectus supplement (offering)
- STROSutro Biopharma8-KCurrent report: shareholder vote
- SPRBSpruce BiosciencesReleaseSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS SymposiumBD extracted 1 program update from this document → SPRB pipeline
- RNTXRein TherapeuticsDEFA14AProxy soliciting material
- RNTXRein TherapeuticsDEF 14AProxy statement
- RNTXRein TherapeuticsARSAnnual report to shareholders
- NRSNNeuroSense Therapeutics6-KForeign issuer report
- NRIXNurix TherapeuticsReleaseNurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
- NRIXNurix Therapeutics8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1BD extracted 4 program updates from this document → NRIX pipeline
- NGNENeurogene8-KCurrent report: Reg FD disclosure · EX-99.1
- LQDALiquidia8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- KYMRKymera TherapeuticsReleasePenny Carlson will oversee global clinical development operations across Kymera’s oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass., June
- KYMRKymera TherapeuticsReleaseKT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer tria
- KYMRKymera Therapeutics8-KCurrent report: officer / director change
- IPSCCentury TherapeuticsReleaseNew CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
- IPSCCentury Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- IONSIonis Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- IDYAIDEAYA Biosciences424B5Prospectus supplement (offering)
- FBRXForte BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- FBRXForte BiosciencesS-3/AShelf registration (amended)
- ELOXEloxx PharmaceuticalsEFFECTRegistration effective
- ELOXEloxx PharmaceuticalsCERTCERT
- DYNDyne Therapeutics8-KCurrent report: shareholder vote
- DBVTDBV TechnologiesReleaseDBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026via aggregator
- CLYMClimb Bio8-KCurrent report: officer / director change, shareholder vote · EX-99.1
- CGONCG Oncology8-KCurrent report: shareholder vote
- CGENCompugenEFFECTRegistration effective
- CGEMCullinan Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- CAPRCapricor Therapeutics8-KCurrent report: shareholder vote
- BEAMBeam Therapeutics8-KCurrent report: shareholder vote
- ATHEAlterity TherapeuticsReleaseAlterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System AtrophyBD extracted 1 program update from this document → ATHE pipeline
- ATAIAtai Beckley8-KCurrent report: shareholder vote
- ARTVArtiva BiotherapeuticsReleaseArtiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast TodayBD extracted 1 program update from this document → ARTV pipeline
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
- ADAGAdageneSCHEDULE 13D/A13D amendment
- ACTUActuate TherapeuticsDRSDRS
- ACHVAchieve Life SciencesDEF 14AProxy statement
- ACHVAchieve Life SciencesARSAnnual report to shareholders
Saturday, June 61
- CGEMCullinan TherapeuticsReleaseCullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 CongressBD extracted 1 program update from this document → CGEM pipeline
Friday, June 526
- XERSXeris Biopharma8-KCurrent report: shareholder vote
- VNDAVanda PharmaceuticalsS-8Employee plan registration
- VNDAVanda Pharmaceuticals8-KCurrent report: shareholder vote
- UNCYUnicycive TherapeuticsS-3Shelf registration
- UNCYUnicycive Therapeutics8-KCurrent report: material agreement
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- SLDBSolid Biosciences424B7Prospectus supplement
- SANASana Biotechnology8-KCurrent report: shareholder vote
- PMVPPMV Pharmaceuticals8-KCurrent report: shareholder vote
- OKUROnKure TherapeuticsS-8Employee plan registration
- NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.BD extracted 1 program update from this document → NRXP pipeline
- NKTRNektar Therapeutics8-KCurrent report: shareholder vote
- NAMSNewAmsterdam PharmaS-8Employee plan registration
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- LGVNLongeveron8-KCurrent report: officer / director change
- JBIOJade BiosciencesReleaseJUNE 5, 2026 Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares
- JBIOJade BiosciencesDEFA14AProxy soliciting material
- IRDOpus GeneticsS-3Shelf registration
- IMMXImmix BiopharmaSCHEDULE 13G/A13G amendment
- GRCEGrace Therapeutics8-KCurrent report: officer / director change
- GPCRStructure TherapeuticsReleaseStructure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for ObesityBD extracted 1 program update from this document → GPCR pipeline
- GOSSGossamer Bio8-KCurrent report: material agreement, agreement terminated, debt / obligation · EX-99.1
- GOSSGossamer Bio8-KCurrent report: shareholder vote
- EWTXEdgewise Therapeutics8-KCurrent report: shareholder vote
- ELOXEloxx PharmaceuticalsSCHEDULE 13G/A13G amendment
- DBVTDBV TechnologiesReleaseDBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conferencevia aggregator
- DBVTDBV Technologies8-KCurrent report: officer / director change
- CRBUCaribou BiosciencesDEFA14AProxy soliciting material
- CLYMClimb BioReleaseClimb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
- CLYMClimb BioCORRESPCORRESP
- CLYMClimb Bio8-KCurrent report: other events
- CLRBCellectar BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- CLNNCleneS-8Employee plan registration
- CABACabaletta BioSCHEDULE 13G/A13G amendment
- BMEABiomea FusionReleaseBiomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 StudyBD extracted 1 program update from this document → BMEA pipeline
- ABSIAbsci8-KCurrent report: shareholder vote
Thursday, June 438
- TVTXTravere TherapeuticsReleaseTravere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 CongressBD extracted 1 program update from this document → TVTX pipeline
- TNGXTango Therapeutics8-KCurrent report: shareholder vote
- TENXTenax Therapeutics8-KCurrent report: shareholder vote
- STOKStoke Therapeutics8-KCurrent report: shareholder vote
- SRPTSarepta TherapeuticsS-8Employee plan registration
- SRPTSarepta Therapeutics8-KCurrent report: officer / director change, shareholder vote
- SNDXSyndax PharmaceuticalsDEFA14AProxy soliciting material
- SNDXSyndax Pharmaceuticals8-KCurrent report: material agreement, debt / obligation, unregistered sale of equity · EX-99.1
- SMMTSummit TherapeuticsReleaseSummit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
- QTTBQ32 BioSCHEDULE 13GPassive >5% holder (13G)
- QTTBQ32 BioSCHEDULE 13GPassive >5% holder (13G)
- QNRXQuoin Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- OVIDOvid TherapeuticsReleaseOvid Therapeutics to Participate in Upcoming Investor Conferences
- ORKAOruka Therapeutics8-KCurrent report: shareholder vote
- OKUROnKure Therapeutics8-KCurrent report: officer / director change, shareholder vote
- NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
- NRXPNRX Pharmaceuticals8-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
- NGNENeurogene8-KCurrent report: shareholder vote
- NAMSNewAmsterdam PharmaSCHEDULE 13G/A13G amendment
- MAIAMAIA BiotechnologyReleaseMAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
- LGVNLongeveronReleaseLongeveron to Present at BIO International Convention 2026
- KURAKura OncologyS-8Employee plan registration
- KURAKura Oncology8-KCurrent report: officer / director change, shareholder vote · EX-99.1
- KODKodiak Sciences8-KCurrent report: shareholder vote
- KAPAKairos Pharma8-KCurrent report: other events · EX-99.1
- JBIOJade BiosciencesReleaseJUNE 4, 2026 Jade Biosciences Announces Pricing of Public Offering of Common Stock
- JBIOJade Biosciences8-KCurrent report: other events · EX-99.1
- JBIOJade Biosciences424B5Prospectus supplement (offering)
- GUTSFractyl HealthReleaseFractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedurevia aggregator
- GUTSFractyl Health8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- GLSIGreenwich LifeSciences10-QQuarterly report
- GHRSGH ResearchReleaseGH Research Announces Publication of Phase 2a Postpartum Depression Results Jun 04, 2026 DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of theBD extracted 1 program update from this document → GHRS pipeline
- GHRSGH Research6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- FATEFate Therapeutics8-KCurrent report: other events · EX-99.1
- ELOXEloxx PharmaceuticalsS-1/ARegistration statement (amended)
- DBVTDBV TechnologiesS-8Employee plan registration
- CYDYCytoDynReleaseNatera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
- CLYMClimb BioUPLOADUPLOAD
- CINGCingulateReleaseStonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26BD extracted 1 program update from this document → CING pipeline
- CGTXCognition Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- CGENCompugenCORRESPCORRESP
- CABACabaletta BioSCHEDULE 13G/A13G amendment
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ARVNArvinasReleaseArvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
- ANTXAN2 Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- AMLXAmylyx Pharmaceuticals8-KCurrent report: shareholder vote
- ACRSAclaris Therapeutics8-KCurrent report: shareholder vote
Wednesday, June 353
- XENEXenon PharmaceuticalsS-8 POSEmployee plan registration (post-effective)
- XENEXenon PharmaceuticalsS-8 POSEmployee plan registration (post-effective)
- XENEXenon PharmaceuticalsS-8 POSEmployee plan registration (post-effective)
- XENEXenon PharmaceuticalsS-8 POSEmployee plan registration (post-effective)
- XENEXenon PharmaceuticalsS-8 POSEmployee plan registration (post-effective)
- XENEXenon PharmaceuticalsS-8 POSEmployee plan registration (post-effective)
- XENEXenon PharmaceuticalsS-8 POSEmployee plan registration (post-effective)
- XENEXenon PharmaceuticalsS-8 POSEmployee plan registration (post-effective)
- XENEXenon PharmaceuticalsS-8 POSEmployee plan registration (post-effective)
- XENEXenon PharmaceuticalsS-8 POSEmployee plan registration (post-effective)
- XENEXenon PharmaceuticalsS-8Employee plan registration
- XENEXenon Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote
- VRDNViridian Therapeutics8-KCurrent report: shareholder vote
- TTRXTurn Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 INVESTOR PRESENTATION, DATED JUNE 3, 2026BD extracted 1 program update from this document → TTRX pipeline
- TGTXTg Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- SYRESpyre TherapeuticsReleaseSpyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpABD extracted 1 program update from this document → SYRE pipeline
- SMMTSummit Therapeutics8-KCurrent report: other events
- SGMTSagimet Biosciences8-KCurrent report: officer / director change
- RCUSArcus BiosciencesReleaseArcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to...BD extracted 1 program update from this document → RCUS pipeline
- RAREUltragenyx PharmaceuticalReleaseUltragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
- PRQRProQR TherapeuticsSCHEDULE 13D/A13D amendment
- OVIDOvid TherapeuticsReleaseOvid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
- OVIDOvid Therapeutics8-KCurrent report: officer / director change
- OCGNOcugen8-KCurrent report: officer / director change
- NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
- NRXPNRX Pharmaceuticals424B5Prospectus supplement (offering)
- NAMSNewAmsterdam Pharma8-KCurrent report: officer / director change, shareholder vote
- MLYSMineralys Therapeutics8-KCurrent report: other events · EX-99.1
- MLYSMineralys Therapeutics8-KCurrent report: material agreement, debt / obligation
- MLYSMineralys Therapeutics424B5Prospectus supplement (offering)
- MDNAFMedicenna TherapeuticsReleaseMedicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
- MAIAMAIA BiotechnologyReleaseMAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial ExpansionBD extracted 2 program updates from this document → MAIA pipeline
- KYTXKyverna TherapeuticsReleaseKyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid ArthritisBD extracted 1 program update from this document → KYTX pipeline
- KURAKura OncologyReleaseKura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development StrategyBD extracted 2 program updates from this document → KURA pipeline
- KROSKeros Therapeutics8-KCurrent report: shareholder vote
- JBIOJade BiosciencesReleaseJUNE 3, 2026 Jade Biosciences Announces Proposed Underwritten Public Offering
- JBIOJade Biosciences424B5Prospectus supplement (offering)
- INBXInhibrx Biosciences8-KCurrent report: shareholder vote
- INABIN8bioReleaseIN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
- IDYAIDEAYA Biosciences8-KCurrent report: other events
- HROWHarrow8-KCurrent report: Reg FD disclosure · EX-99.1
- GOSSGossamer BioReleaseGossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
- EYPTEyePointSCHEDULE 13GPassive >5% holder (13G)
- ENTXEntera BioDEFA14AProxy soliciting material
- ENTXEntera BioDEF 14AProxy statement
- ENTXEntera BioARSAnnual report to shareholders
- DYNDyne TherapeuticsReleaseDyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)BD extracted 1 program update from this document → DYN pipeline
- DYNDyne Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JUNE 3, 2026
- DBVTDBV TechnologiesReleaseInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026via aggregator
- DBVTDBV Technologies8-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- CUECue BiopharmaS-8Employee plan registration
- CUECue BiopharmaS-3Shelf registration
- CUECue Biopharma8-KCurrent report: officer / director change, shareholder vote
- CTMXCytomX TherapeuticsReleaseCytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- CTMXCytomX Therapeutics8-KCurrent report: material agreement
- CBIOCrescent Biopharma8-KCurrent report: shareholder vote
- CATXPerspective TherapeuticsReleasePerspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a StudyBD extracted 1 program update from this document → CATX pipeline
- CABACabaletta BioReleaseCabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 CongressBD extracted 2 program updates from this document → CABA pipeline
- CABACabaletta Bio8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- BMEABiomea FusionReleaseBiomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in ObesityBD extracted 1 program update from this document → BMEA pipeline
- BCTXBriaCell Therapeutics8-KCurrent report: material agreement, unregistered sale of equity, other events · EX-99.1
- AXSMAxsome Therapeutics8-KCurrent report: other events · EX-99.1
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ATAIAtai Beckley8-KCurrent report: Reg FD disclosure
- ADCTADC Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- ABOSAcumen Pharmaceuticals8-KCurrent report: shareholder vote
Tuesday, June 249
- WVEWave Life SciencesReleaseEco Wave Power Featured for Second Time in NVIDIA Founder and CEO Jensen Huang's GTC Keynote, as Company Advances Taiwan Wave Energy Projectvia aggregator
- VERAVera TherapeuticsReleaseVera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA NephropathyBD extracted 1 program update from this document → VERA pipeline
- VERAVera Therapeutics8-KCurrent report: other events
- TYRATyra Biosciences8-KCurrent report: shareholder vote
- TVTXTravere TherapeuticsReleaseTravere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney DiseasesBD extracted 1 program update from this document → TVTX pipeline
- TVTXTravere Therapeutics8-KCurrent report: material agreement
- TSHATaysha Gene Therapies8-KCurrent report: shareholder vote
- SLSSELLAS Life Sciences Group8-KCurrent report: other events
- QNRXQuoin PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- QNRXQuoin Pharmaceuticals424B3Prospectus (resale / update)
- PRQRProQR Therapeutics6-KForeign issuer report
- ONCYOncolytics Biotech8-KCurrent report: officer / director change, other events · EX-99.1
- OCGNOcugenReleaseOcugen to Participate in Upcoming June Investor and Industry Conferences
- NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
- NRXPNRX Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- NRXPNRX Pharmaceuticals424B5Prospectus supplement (offering)
- MAIAMAIA BiotechnologyReleaseMAIA Biotechnology Announces Open Market Purchases by CEO and Director
- LEGNLegend Biotech6-KForeign issuer report · EX-99.1 PRESS RELEASE
- KZIAKazia Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JUNE 2, 2026
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KYTXKyverna Therapeutics8-KCurrent report: shareholder vote
- KURAKura OncologyReleaseKura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AMLBD extracted 1 program update from this document → KURA pipeline
- KTTAPasithea TherapeuticsReleasePasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)BD extracted 2 program updates from this document → KTTA pipeline
- INMBInmune Bio8-KCurrent report: other events · EX-99.1 PRESS RELEASE DATED JUNE 2, 2026
- IMTXImmatics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- GOSSGossamer BioReleaseGossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
- GOSSGossamer Bio8-KCurrent report: other events · EX-99.1
- FBRXForte BiosciencesS-8Employee plan registration
- FBRXForte BiosciencesS-3Shelf registration
- FBRXForte Biosciences8-KCurrent report: officer / director change, shareholder vote
- EVMNEvommune8-KCurrent report: shareholder vote
- EVMNEvommune424B3Prospectus (resale / update)
- DBVTDBV TechnologiesReleaseDBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
- CUECue Biopharma8-KCurrent report: officer / director change, other events
- CRNXCrinetics PharmaceuticalsReleaseCrinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communitiescompany site may be offline after the acquisition
- CRNXCrinetics PharmaceuticalsReleaseCrinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six PresentationsBD extracted 2 program updates from this document → CRNX pipelinecompany site may be offline after the acquisition
- CMMBChemomab Therapeutics6-KForeign issuer report
- CLRBCellectar Biosciences424B3Prospectus (resale / update)
- CINGCingulateReleaseCingulate Receives Complete Response Letter from FDA for CTx-1301
- CINGCingulate8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → CING pipeline
- CBIOCrescent BiopharmaReleaseCrescent Biopharma to Present at June Investor Conferences
- BCTXBriaCell Therapeutics424B5Prospectus supplement (offering)
- ARVNArvinas8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- ALDXAldeyra TherapeuticsReleaseAldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- ADMAAdma Biologics8-KCurrent report: shareholder vote
- ADCTADC Therapeutics8-KCurrent report: shareholder vote
- ACHVAchieve Life Sciences8-KCurrent report: officer / director change
- ABVXAbivax6-KForeign issuer report · EX-99.1
Monday, June 152
- WVEWave Life SciencesReleaseWave Life Sciences to Present at Upcoming Investor Conferences
- VYGRVoyager TherapeuticsReleaseVoyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
- VYGRVoyager Therapeutics8-KCurrent report: other events
- TTRXTurn TherapeuticsReleaseTurn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
- TTRXTurn Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED JUNE 1, 2026BD extracted 1 program update from this document → TTRX pipeline
- SYRESpyre Therapeutics8-KCurrent report: other events
- SRPTSarepta TherapeuticsReleaseSarepta Therapeutics to Participate in Upcoming Investor Conferencesvia aggregator
- SMMTSummit Therapeutics8-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → SMMT pipeline
- SLDBSolid BiosciencesReleaseSolid Biosciences to Participate at Upcoming Investor Conferences
- QTTBQ32 BioSCHEDULE 13D/A13D amendment
- PYPDPolyPid6-KForeign issuer report · EX-99.1 PRESS RELEASE ISSUED BY POLYPID LTD. ON JUNE 1, 2026, TITLED "POLYPID COMPLETES
- OTLKOutlook TherapeuticsSCHEDULE 13D/A13D amendment
- OTLKOutlook TherapeuticsReleaseOutlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
- OTLKOutlook TherapeuticsDEFA14AProxy soliciting material
- OTLKOutlook TherapeuticsDEF 14AProxy statement
- OTLKOutlook Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- ORKAOruka Therapeutics8-KCurrent report: other events
- ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
- OCSOculis Holding6-KForeign issuer report · EX-99.1
- NTLAIntellia TherapeuticsReleaseIntellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026BD extracted 1 program update from this document → NTLA pipeline
- NGENNervGen Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- MLTXMoonLake Immunotherapeutics8-KCurrent report: material agreement
- MAIAMAIA BiotechnologyReleaseMAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical OncologyBD extracted 1 program update from this document → MAIA pipeline
- LEGNLegend Biotech6-KForeign issuer report · EX-99.1 PRESS RELEASE
- KROSKeros Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
- JBIOJade BiosciencesReleaseJUNE 1, 2026 Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
- JBIOJade Biosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 2 program updates from this document → JBIO pipeline
- INABIN8bioReleaseIN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
- INABIN8bio8-KCurrent report: material agreement, agreement terminated
- INABIN8bio424B5Prospectus supplement (offering)
- IMTXImmaticsReleaseImmatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual MeetingBD extracted 1 program update from this document → IMTX pipeline
- IMTXImmatics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- IMRXImmuneeringReleaseImmuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCOBD extracted 1 program update from this document → IMRX pipeline
- IMRXImmuneering8-KCurrent report: other events
- IDYAIDEAYA Biosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- IBRXImmunityBioReleaseImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026BD extracted 1 program update from this document → IBRX pipeline
- HELPHelus PharmaReleaseHelus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
- HELPHelus Pharma6-KForeign issuer report · EX-99.1
- GUTSFractyl HealthReleaseFractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategyvia aggregator
- GLSIGreenwich LifeSciencesReleaseGreenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026BD extracted 1 program update from this document → GLSI pipeline
- GLSIGreenwich LifeSciences10-KAnnual report
- EWTXEdgewise Therapeutics8-KCurrent report: material agreement · EX-99.1
- ELOXEloxx PharmaceuticalsS-1/ARegistration statement (amended)
- ELOXEloxx Pharmaceuticals8-KCurrent report: unregistered sale of equity, holder rights modified, officer / director change
- ELOXEloxx Pharmaceuticals8-A12B8-A12B
- EIKNEikon Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JUNE 1, 2026BD extracted 1 program update from this document → DRTS pipeline
- CNTBConnect BiopharmaEFFECTRegistration effective
- CLRBCellectar BiosciencesReleaseCellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology AnnBD extracted 1 program update from this document → CLRB pipeline
- CLRBCellectar BiosciencesEFFECTRegistration effective
- CHRSCoherus Oncology8-KCurrent report: shareholder vote
- CGTXCognition TherapeuticsReleaseCognition Therapeutics Participating in Upcoming Investor Conferences
- CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1
- CABACabaletta BioDEFA14AProxy soliciting material
- ACTUActuate TherapeuticsReleaseACTUATE THERAPEUTICS ANNOUNCES ASCO POSTER PRESENTATIONS DEMONSTRATING COMPELLING CLINICAL AND BIOMARKER DATA FOR ELRAGLUSIB IN FIRST-LINE METASTATIC PANCREATIC CANCERBD extracted 1 program update from this document → ACTU pipeline